Researchers, Eugene Merzon, et al. have published findings from a recent study examining correlations between the use of aspirin for the primary prevention of cardiovascular disease and the lower likelihood of COVID‐19 infection in The FEBS Journal.
Search Results for: COVID
A randomized research study sponsored by Washington University School of Medicine seeks participants age 30 and older, who have tested positive for COVID-19, and are currently experiencing mild symptoms.
Dr. John Aucott, Director of The Lyme Disease Research Center, Division of Rheumatology, Department of Medicine at Johns Hopkins University School of Medicine, et al. published the article, “Long-haul COVID: heed the lessons from other infection-triggered illnesses” in The Lancet.
A peer-reviewed report co-authored by Melissa C Fesler and Raphael B Stricker has been published in the International Journal of General Medicine which evaluates pre-exposure prophylaxis (PrEP) using medications approved for use in pregnant women to prevent gestational problems and severe illness in this high-risk population.
Lyme Test/Lyme Neuropathologies/Military: Lyme Myths/Tick Bite/CDC: COVID Vaccine/Hopkins: IDSA, Lyme-COVID/FDA Clears PhageBank/HHS WG ’20 Report/Lyme Boundaries/Longhorned Tick Spread/J&J Vaccine/Babesiosis Increase
As part of the LymeX public-private partnership between Health & Human Services (HHS) and the Cohen Foundation, HHS has published an RFI in the Federal Register, 2.11.21 that seeks information on the current state of the science and technology to accelerate “innovative solutions” for Lyme disease diagnosis.
Update 2/27/21: The FDA has approved J&J’s Covid-19 vaccine for emergency use Feb. 24, 2021– the Food & Drug Administration (FDA) has indicated Johnson & Johnson’s COVID-19 vaccine has met […]
The Centers for Disease Control and Prevention (CDC) has provided an update in the federal agency’s Morbidity and Mortality Weekly Report (MMWR) on February 19, 2021, regarding the first month of COVID-19 […]
Adaptive Phage Therapeutics (APT) announced the US Food and Drug Administration (FDA) clearance of the Expanded Access IND for PhageBank™ treatment for pneumonia or bacteremia/septicemia due to Acinetobacter baumannii, Pseudomonas aeruginosa or Staphylococcus […]
Johns Hopkins Lyme Disease Research Center’s recently released Winter 2021 Newsletter addresses the confusing new IDSA guidelines, calls attention to the similarities between common COVID-19 long hauler symptoms and persistent Lyme disease, as well as provides insights to significant advances made by their Lyme disease clinical research program, despite challenges brought by the COVID-19 pandemic.